The research team, led by researchers at the Universities of Cambridge and Edinburgh and biotech company BD Bioscience, worked across four sites in the U.K. They identified markers on three immune cells that are linked to a higher risk of these secondary infections. The markers do not show what kind of secondary infection an individual may get, but indicate that they are generally more susceptible to secondary infections.
“These markers help us create a ‘risk profile’ for an individual,” Andrew Conway Morris, PhD, from the Department of Medicine at the University of Cambridge said in a news release. “This tells us who is at greatest risk of developing a secondary infection. In the long term, this will help us target therapies at those most at risk, but it will be immediately useful in helping identify individuals to take part in clinical trials of new treatments.”
Since it is often difficult to identify and recruit the patients most susceptible to these infections for clinical trials, the test could help tailor participant selection and improve the trials’ chances for success.
“As intensive care specialists, our priority is to prevent patients developing secondary infections and, if they do, to ensure they get the best treatment,” said senior study author Tim Walsh from the University of Edinburgh.
More articles on clinical leadership and infection control:
A World Cup-prompted measles outbreak? 3 things to consider
Postsurgery VTE linked to perioperative blood cell transfusions
Study: Researchers create model to study humans’ behavioral response to epidemics
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
